Study underway to evaluate immunotherapy plus radiotherapy for newly diagnosed sarcoma

A clinical trial is underway to assess use of two immunotherapy agents, durvalumab and tremelimumab, plus radiation therapy for the treatment of newly diagnosed high-risk sarcoma. The goal of the Neoadjuvant XRT Immunotherapy and Surgery for Soft Tissue Sarcoma (NEXIS) trial is to stimulate the immune system with the combined treatment regimen to destroy a patient’s initial tumour and any remaining microscopic cancer cells that may spore other tumours.